Whalesbook Logo
Whalesbook
HomeStocksNewsPremiumAbout UsContact Us

Pitti Engineering: Deven Choksey Maintains 'BUY' Rating with INR 1,080 Target After Strong Q2 FY26 Results

Industrial Goods/Services

|

Published on 17th November 2025, 8:16 AM

Whalesbook Logo

Author

Satyam Jha | Whalesbook News Team

Overview

Pitti Engineering reported a strong Q2 FY26 with revenue growing 11.3% year-on-year to INR 4,777 million, exceeding analyst estimates by 11%. This growth was driven by robust operational performance and resilient export demand across key sectors. Analyst Deven Choksey reiterated a 'BUY' rating for the stock, setting a target price of INR 1,080 based on September 2027 estimates.

Pitti Engineering: Deven Choksey Maintains 'BUY' Rating with INR 1,080 Target After Strong Q2 FY26 Results

Stocks Mentioned

Pitti Engineering

Pitti Engineering has announced its financial results for the second quarter of Fiscal Year 2026 (Q2 FY26), showcasing significant year-on-year growth.

Q2 FY26 Performance

The company's revenue reached INR 4,777 million, marking an 11.3% increase compared to the same period last year. This figure also surpassed analyst expectations by approximately 11%. The impressive performance was attributed to several factors, including stronger operational traction from increased machining hours, improved utilization rates in casting operations, and a higher contribution from value-added integrated assemblies. Additionally, resilient export demand from critical segments such as rail traction, power equipment, and data centers provided further support.

Outlook and Valuation

Looking ahead, the company's valuation basis has been updated to incorporate estimates for September 2027. Pitti Engineering is being valued at 19.0 times its projected Earnings Per Share (EPS) for September 2027. This valuation method leads to a target price of INR 1,080 for the stock.

Analyst Recommendation

Following these results and the updated outlook, analyst Deven Choksey has reiterated a 'BUY' rating on Pitti Engineering, signalling confidence in the company's future prospects.

Impact

Rating: 7/10

This news is highly positive for Pitti Engineering investors. The stronger-than-expected Q2 results and the reaffirmation of a 'BUY' rating with a substantial target price suggest a potential upward movement in the stock. The robust performance in key export segments also points to positive long-term trends for the company. Investors are likely to react favorably, which could lead to increased demand for the stock.


Healthcare/Biotech Sector

Delhi High Court Mandates WHO Formula for 'ORS' Labeling, Upholds Food Safety Standards

Delhi High Court Mandates WHO Formula for 'ORS' Labeling, Upholds Food Safety Standards

Pfizer India Introduces Rimegepant ODT, a New Migraine Treatment Option

Pfizer India Introduces Rimegepant ODT, a New Migraine Treatment Option

Granules India: Motilal Oswal Research Points to Strong Operations, Sets INR 650 Target

Granules India: Motilal Oswal Research Points to Strong Operations, Sets INR 650 Target

Delhi High Court Mandates WHO Formula for 'ORS' Labeling, Upholds Food Safety Standards

Delhi High Court Mandates WHO Formula for 'ORS' Labeling, Upholds Food Safety Standards

Pfizer India Introduces Rimegepant ODT, a New Migraine Treatment Option

Pfizer India Introduces Rimegepant ODT, a New Migraine Treatment Option

Granules India: Motilal Oswal Research Points to Strong Operations, Sets INR 650 Target

Granules India: Motilal Oswal Research Points to Strong Operations, Sets INR 650 Target


Brokerage Reports Sector

SBI Securities Picks City Union Bank, Belrise Industries; Nifty, Bank Nifty Surge to New Highs

SBI Securities Picks City Union Bank, Belrise Industries; Nifty, Bank Nifty Surge to New Highs

Alkem Laboratories: Motilal Oswal Research Highlights Strong Q4 Performance and Positive Outlook

Alkem Laboratories: Motilal Oswal Research Highlights Strong Q4 Performance and Positive Outlook

Motilal Oswal Maintains BUY on Bharat Dynamics, Revises Target Price to ₹2,000 on Strong Order Book and Execution

Motilal Oswal Maintains BUY on Bharat Dynamics, Revises Target Price to ₹2,000 on Strong Order Book and Execution

Granules India Stock: Analyst Deven Choksey Sets ₹588 Target, Revises Rating to ACCUMULATE After Strong Q2FY26 Results

Granules India Stock: Analyst Deven Choksey Sets ₹588 Target, Revises Rating to ACCUMULATE After Strong Q2FY26 Results

Ipca Laboratories Stock Sees 'BUY' Rating from Motilal Oswal on Strong Q2 Performance and Growth Outlook

Ipca Laboratories Stock Sees 'BUY' Rating from Motilal Oswal on Strong Q2 Performance and Growth Outlook

Indian Bank Retains BUY Rating With Rs900 Target Price by Emkay Global Financial

Indian Bank Retains BUY Rating With Rs900 Target Price by Emkay Global Financial

SBI Securities Picks City Union Bank, Belrise Industries; Nifty, Bank Nifty Surge to New Highs

SBI Securities Picks City Union Bank, Belrise Industries; Nifty, Bank Nifty Surge to New Highs

Alkem Laboratories: Motilal Oswal Research Highlights Strong Q4 Performance and Positive Outlook

Alkem Laboratories: Motilal Oswal Research Highlights Strong Q4 Performance and Positive Outlook

Motilal Oswal Maintains BUY on Bharat Dynamics, Revises Target Price to ₹2,000 on Strong Order Book and Execution

Motilal Oswal Maintains BUY on Bharat Dynamics, Revises Target Price to ₹2,000 on Strong Order Book and Execution

Granules India Stock: Analyst Deven Choksey Sets ₹588 Target, Revises Rating to ACCUMULATE After Strong Q2FY26 Results

Granules India Stock: Analyst Deven Choksey Sets ₹588 Target, Revises Rating to ACCUMULATE After Strong Q2FY26 Results

Ipca Laboratories Stock Sees 'BUY' Rating from Motilal Oswal on Strong Q2 Performance and Growth Outlook

Ipca Laboratories Stock Sees 'BUY' Rating from Motilal Oswal on Strong Q2 Performance and Growth Outlook

Indian Bank Retains BUY Rating With Rs900 Target Price by Emkay Global Financial

Indian Bank Retains BUY Rating With Rs900 Target Price by Emkay Global Financial